Affibody

Executive Summary

Affibody is a Swedish biotechnology company developing next-generation radiopharmaceuticals based on its proprietary Affibody® platform, which enables precision-targeted radioligand therapies (RLTs) for a broad range of cancers. Founded in 1998 and headquartered in Solna, the company is currently in Phase 1 clinical development. Its lead program targets solid tumors, leveraging small engineered scaffold proteins (Affibody molecules) for high-affinity binding and favorable pharmacokinetics. Beyond oncology, Affibody has partnered programs in immunology, notably izokibep (a novel IL-17A inhibitor) for hidradenitis suppurativa, which is being developed with a partner. The company's approach aims to improve therapeutic index and reduce off-target toxicity compared to traditional antibody-based RLTs. With a validated platform and early clinical data, Affibody is positioned to address significant unmet needs in radiopharmaceutical therapy.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead RLT candidate60% success
• Q2 2027Initiation of Phase 2 study for lead program40% success
• Q1 2027Partnered izokibep Phase 2b/3 data in hidradenitis suppurativa50% success